Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study
- 1Department of Endocrinology and Metabolism, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
- 2Department of Diabetes and Endocrinology Kyoto Okamoto Memorial Hospital Kumiyama Japan
- 3Department of Diabetology Kameoka Municipal Hospital Kyoto Japan
Abstract
Aims To investigate the long‐term renal effects of tofogliflozin, with the shortest half‐life among sodium–glucose cotransporter 2 inhibitors, in real‐world clinical practice. Materials and methods We retrospectively enrolled patients with type 2 diabetes mellitus treated at three affiliated hospitals between January 2015 and May 2024. The primary outcome was the change in estimated glomerular filtration rate from baseline to 72 months. After inverse probability of treatment weighting, linear mixed‐effects models were used to compare estimated glomerular filtration rate changes between the tofogliflozin and non‐tofogliflozin groups. As a sensitivity analysis, multiple imputation was performed to address missing baseline urinary albumin‐to‐creatinine ratio data. Secondary outcomes included estimated glomerular filtration rate slopes, changes in glycated hemoglobin and body weight at 72 months, and changes in urinary albumin‐to‐creatinine ratio at 48 months. Results Among 598 participants (tofogliflozin, n = 245; non‐tofogliflozin, n = 353), estimated glomerular filtration rate decline was significantly slower in the tofogliflozin group than in the non‐tofogliflozin group (P < 0.001). At 72 months, the least squares mean estimated glomerular filtration rate change was −4.51 and −10.64 mL/min/1.73 m2, respectively (between‐group difference: 6.14 mL/min/1.73 m2). Significant between‐group differences were observed in estimated glomerular filtration rate slope, glycated hemoglobin, and body weight, but not in urinary albumin‐to‐creatinine ratio. Renal findings were consistent in the multiple imputation sensitivity analysis. Conclusions Real‐world clinical data over 72 months suggested that tofogliflozin may slow estimated glomerular filtration rate decline.
Related
- Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan
- Renal function trajectories before and during the COVID-19 pandemic in Japanese individuals with type 1 diabetes: a post-hoc analysis of the multicenter retrospective investigation by the IPRA-CKD study group
- Use of SGLT2 Inhibitors, GLP‐1 Receptor Agonists, and DPP‐4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations
- Sodium-glucose cotransporter 2 inhibitor tofogliflozin ameliorates insulin signaling by improving mitochondrial function in the podocytes in DKD
- 971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study
BibTeX
@article{shinagawa2026longterm,
title = {{Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study}},
author = {Natsuko Shinagawa and Hiroshi Okada and Junya Hironaka and Shinta Yamamoto and Mari Yoneda and Sayaka Kawai and Yuto Saijyo and Tomoya Katayama and Hanako Nakajima and Akio Kishi and Noriyuki Kitagawa and Naoko Nakanishi and Masahide Hamaguchi and Michiaki Fukui},
journal = {Journal of Diabetes Investigation},
year = {2026},
month = nov,
doi = {10.1111/jdi.70445},
url = {https://doi.org/10.1111/jdi.70445},
note = {CC BY},
}
RIS
TY - JOUR
TI - Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study
AU - Natsuko Shinagawa
AU - Hiroshi Okada
AU - Junya Hironaka
AU - Shinta Yamamoto
AU - Mari Yoneda
AU - Sayaka Kawai
AU - Yuto Saijyo
AU - Tomoya Katayama
AU - Hanako Nakajima
AU - Akio Kishi
AU - Noriyuki Kitagawa
AU - Naoko Nakanishi
AU - Masahide Hamaguchi
AU - Michiaki Fukui
PY - 2026
DA - 2026/11/02
JO - Journal of Diabetes Investigation
DO - 10.1111/jdi.70445
UR - https://doi.org/10.1111/jdi.70445
AB - Aims To investigate the long‐term renal effects of tofogliflozin, with the shortest half‐life among sodium–glucose cotransporter 2 inhibitors, in real‐world clinical practice. Materials and methods We retrospectively enrolled patients with type 2 diabetes mellitus treated at three affiliated hospitals between January 2015 and May 2024. The primary outcome was the change in estimated glomerular filtration rate from baseline to 72 months. After inverse probability of treatment weighting, linear mixed‐effects models were used to compare estimated glomerular filtration rate changes between the tofogliflozin and non‐tofogliflozin groups. As a sensitivity analysis, multiple imputation was performed to address missing baseline urinary albumin‐to‐creatinine ratio data. Secondary outcomes included estimated glomerular filtration rate slopes, changes in glycated hemoglobin and body weight at 72 months, and changes in urinary albumin‐to‐creatinine ratio at 48 months. Results Among 598 participants (tofogliflozin, n = 245; non‐tofogliflozin, n = 353), estimated glomerular filtration rate decline was significantly slower in the tofogliflozin group than in the non‐tofogliflozin group (P < 0.001). At 72 months, the least squares mean estimated glomerular filtration rate change was −4.51 and −10.64 mL/min/1.73 m2, respectively (between‐group difference: 6.14 mL/min/1.73 m2). Significant between‐group differences were observed in estimated glomerular filtration rate slope, glycated hemoglobin, and body weight, but not in urinary albumin‐to‐creatinine ratio. Renal findings were consistent in the multiple imputation sensitivity analysis. Conclusions Real‐world clinical data over 72 months suggested that tofogliflozin may slow estimated glomerular filtration rate decline.
SN - 2040-1124
SN - 2040-1116
ER -